Brokerages Set Biohaven Ltd. (NYSE:BHVN) Price Target at $22.27

Shares of Biohaven Ltd. (NYSE:BHVN) have been given an average recommendation of “Moderate Buy” by the seventeen brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, nine have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $22.2667.

A number of brokerages have commented on BHVN. Wall Street Zen downgraded Biohaven from a “sell” rating to a “strong sell” rating in a research note on Sunday, April 26th. Leerink Partners restated an “outperform” rating and issued a $15.00 target price on shares of Biohaven in a research note on Tuesday, March 3rd. HC Wainwright restated a “neutral” rating and issued a $10.00 target price on shares of Biohaven in a research note on Tuesday, May 26th. Raymond James Financial restated a “strong-buy” rating on shares of Biohaven in a research note on Wednesday, May 27th. Finally, Citigroup boosted their target price on Biohaven from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd.

Biohaven Stock Performance

Shares of BHVN stock opened at $11.11 on Friday. Biohaven has a 1-year low of $7.48 and a 1-year high of $18.57. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 1.87. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -1.96 and a beta of 1.35. The stock’s fifty day simple moving average is $9.84 and its 200-day simple moving average is $10.47.

Biohaven (NYSE:BHVN) last issued its earnings results on Monday, May 4th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). On average, sell-side analysts predict that Biohaven will post -3.07 earnings per share for the current fiscal year.

Institutional Trading of Biohaven

Large investors have recently made changes to their positions in the stock. Aberdeen Group plc bought a new stake in shares of Biohaven during the 4th quarter worth about $7,829,000. Capital Research Global Investors boosted its stake in shares of Biohaven by 108.9% during the 3rd quarter. Capital Research Global Investors now owns 1,011,530 shares of the company’s stock worth $15,183,000 after acquiring an additional 527,337 shares in the last quarter. Integral Health Asset Management LLC boosted its stake in shares of Biohaven by 116.7% during the 3rd quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $9,756,000 after acquiring an additional 350,000 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Biohaven by 291.8% during the 4th quarter. SG Americas Securities LLC now owns 105,518 shares of the company’s stock worth $1,191,000 after acquiring an additional 78,585 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in shares of Biohaven by 484.7% during the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 133,900 shares of the company’s stock worth $1,512,000 after acquiring an additional 111,000 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.